Year Author Study Type Size Summary
2009
Nienaber et al. (INSTEAD)
Clinical trial
Total: 140 TEVAR with OMT: 72 OMT only: 68
No significant difference in all-cause mortality at 2 years between TEVAR with OMT and OMT only groups (P=0.15).
2013
Nienaber et al. (INSTEAD-XL)
Clinical trial
Total: 140 TEVAR with OMT: 72 OMT only: 68
No significant difference in all-cause mortality during follow-up period (2-5 years) between TEVAR with OMT (11.1%) and OMT only (19.3%) groups (P=0.13).
2014
Brunkwall et al. (1-year Results of the ADSORB Trial)
Clinical trial
Total: 61 TEVAR with BMT: 30 BMT only: 31
One death due to cardiac arrest in TEVAR with BMT group recorded.
2016
Qin et al.
Observational study
Total: 338 TEVAR with OMT: 184 OMT only: 154 Total of 50 late (>30 days) deaths observed (27 aortic-related; 18 unrelated to dissection; 5 unknown). All-cause mortality significantly lower for TEVAR with OMT group (P=0.01).
2017
Enezate et al.
Systematic review and meta-analysis
6 studies Total: 1960
No significant difference between BMT and TEVAR all-cause mortality in short-term (30 days; P=0.15), intermediate (1 year; P=0.96) and mid-term (2-5 years; P=0.75).
2018
Tjaden Jr. et al.
Observational study
Total: 264 Acute TBAD: 170 (un-TBAD 69; co-TBAD 101) Chronic TBAD: 94 (un-TBAD 40; co-TBAD 54) Overall all-cause mortality is 12.5% in follow-up period (mean 26 months). Significantly lower all-cause mortality rate for acute TBAD (P=0.02). Multivariate analysis shows overall survival significantly higher for acute un-TBAD (93%) compared to other subtypes (83%) at 2 years (P<0.05).
2018
Iannuzzi et al.
Observational study
Total: 9165 OMT: 95% TEVAR: 2.9% Open repair: 2% 1-year survivals (OMT: 84%; TEVAR: 85%; Open repair: 76%) and 5-year survivals (OMT: 60%; TEVAR: 76%; Open repair: 67%) (P<0.01). Risk-adjusted multivariable analysis shows significantly improved survival for TEVAR compared with OMT (P<0.01) and no significant difference between OMT and open repair (P<0.01).
2020
Hossack et al.
Systematic review and meta-analysis
6 studies Total: 14706 (TEVAR: 1066)
Significantly lower risk of all-cause mortality (P<0.001) and aorta related mortality (P=0.001) for TEVAR when compared to BMT.
2020
Torrent et al.
Observational study
Total: 688 Acute un-TBAD: 446 Subacute un-TBAD: 242 1-year mortality for acute and subacute un-TBAD patients undergoing TEVAR (13.3% and 8.2% respectively; P=0.129). After propensity score matching 1- year mortality for acute and subacute patients (12.4% and 9.9% respectively; P=0.5).
2020
Bi et al.
Observational study
Total: 53 Acute TBAD with TEVAR: 22 Subacute TBAD with TEVAR: 18 Non-operative: 13
3-year survival rates for acute TBAD with TEVAR, subacute TBAD with TEVAR, non-operative groups (95.5%, 100%, 85.7% respectively).
2021
Spinelli et al.
Observational study
Total: 172 Acute un-TBAD with TEVAR: 70 Acute co-TBAD with TEVAR: 102
No significant difference in overall survival between co-TBAD and un-TBAD patients at 1 year (88.8%±11.2% versus 96.8%±3.1%) and 3 years (79.1%±20.8% vs 90.4% ±9.5%), (P=0.138).
2021
Xie et al.
Observational study
Total: 267 Acute un-TBAD: 130 Subacute un-TBAD: 137 Cumulative survival rate from all-cause mortality at 5 years for acute (94.2%; 95% CI 89.1% - 95.7%) and subacute (88.3%;95% CI 81.5% e 95.7%) groups. No significant difference in all-cause mortality between the 2 groups (Log rank P=0.24).
2021
Xiang et al.
Observational study
Total: 357 TEVAR: 191 BMT: 166
Freedom from all-cause mortality higher in TEVAR group than BMT group at 1 (97.2% versus 94.2%), 3 (96.4% versus 88.5%) and 5 years (91.9% versus 82.2%) (P=0.028).
2021
Xiang et al.
Observational study
Total: 238 Acute with TEVAR: 142 Subacute with TEVAR: 96 10 all-cause death in acute group versus 9 in subacute group at 5 years. Landmark analysis reveals comparable all-cause mortality rates between 2 groups at 1 year (P=0.38) and between 1-5 years (P=0.15).